- All > Medicine Information and Evidence for Policy > Medicines Policy
- All > Medicine Access and Rational Use > Antimicrobial Drug Resistance
- Keywords > action plan
- Keywords > antimicrobial containment
- Keywords > antimicrobial resistance (AMR)
- Keywords > antimicrobial resistance surveillance
- Keywords > containment of antimicrobial resistance
- Keywords > Global Antimicrobial Resistance Surveillance System (GLASS)
- Keywords > rational use of antibiotics
- Keywords > surveillance - antibiotic resistance and antibiotic use
(2018; 260 pages)
The Global Antimicrobial Resistance Surveillance System (GLASS) Report: Early Implementation 2016-17 draws information from GLASS enrolled countries on the status of their AMR surveillance systems, and reports official national AMR data for selected bacteria that cause infections in humans: Acinetobacter spp., Escherichia coli, Klebsiella pneumoniae, Neisseria gonorrhoeae, Salmonella spp., Shigella spp., Staphylococcus aureus, and Streptococcus pneumoniae.
By the end of the first GLASS data call on 8 July 2017, 42 countries were enrolled in GLASS, of which 40 countries provided information on their AMR surveillance systems, and 22 provided 2016 AMR data. The aim of the report is to document participation efforts and outcomes across countries, and highlight differences and constraints identified to date. In this first GLASS report data vary considerably in terms of completeness, so no attempt was made to compare AMR status at a regional or global level. However, as GLASS and country participation evolves, the data reported will help understand surveillance capacities and mechanisms of reporting across countries in all regions, and will inform further GLASS development.